Royalty Pharma PLC
Company Overview: Royalty Pharma plc (NASDAQ: RPRX) is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products and 10 development-stage product candidates.
As per our previous report published on RPRX on 10th May 2022, Kalkine provided a ‘BUY’ stance on the stock at USD 37.53 based on ‘royalties receipts, leading margin profile, and upside indicated based on Valuation done, and the stock price has now moved by ~16.28% since then and the price is now moved above the Resistance 1 level and heading towards its resistance R2.
Noted below are the details of support and resistance levels provided in our previous report:
RPRX’s Daily Chart
(Source: Refinitiv, Analysis done by Kalkine Group)
Considering the resistance, target level attainment, current trading levels, risks associated, and volatile market condition on the back of rising interest rates, a ‘Sell’ rating is assigned to the “RPRX” at the closing market price of USD 43.64 (as of 12 September 2022).
Note: This report may be updated with details around fundamental and technical analysis, price/ chart in due course, as appropriate
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 10th May 2022. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.
Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’